Cutera® Announces Second Quarter 2024 Financial Results

Rhea-AI Summary

Cutera Inc. (Nasdaq: CUTR) reported Q2 2024 financial results with consolidated revenue of $34.4 million, a 44% decrease compared to Q2 2023. Key highlights include:

- AviClear growth of 41% vs prior year period
- Service growth of 7% vs prior year period
- Cash, cash equivalents, and restricted cash of $84.3 million
- Completion of Q4 2023 corporate restructuring program
- Additional $10 million cost reduction opportunity identified

The company revised its full-year revenue guidance to $140-$145 million and updated cash guidance to approximately $40 million by year-end. Steve Kreider was promoted to SVP, North America, to lead the combined North American commercial organization.

Positive

• AviClear growth of 41% compared to prior year period
• Service revenue growth of 7% compared to prior year period
• Completion of Q4 2023 corporate restructuring program, resulting in $20 million annualized expense savings
• Identification of additional $10 million cost reduction opportunity for 2025
• Cash, cash equivalents, and restricted cash of $84.3 million as of June 30, 2024

Negative

• Consolidated revenue decreased by 44% to $34.4 million compared to Q2 2023
• Capital systems sales revenue declined by 39%
• Recurring revenue sources, excluding skincare, declined by 20%
• Gross profit margin decreased to 22.2% from 42.2% in Q2 2023
• Operating loss of $21.8 million for Q2 2024
• Downward revision of full-year revenue guidance to $140-$145 million from previous $160-$170 million
• Cash guidance lowered to approximately $40 million by year-end 2024

Insights

Financial Analyst

Cutera's Q2 2024 results reveal significant challenges. Revenue of $34.4 million represents a 44% decline year-over-year, with capital system sales down 39% and recurring revenue (excluding skincare) down 20%. The gross profit margin deteriorated to 22.2% from 42.2% in Q2 2023, partly due to $2.4 million in excess inventory expenses.

The company's cash position decreased from $105.4 million in Q1 to $84.3 million, indicating substantial cash burn. Management has revised full-year revenue guidance down to $140-145 million from $160-170 million and expects cash to further decline to $40 million by year-end.

While cost-cutting measures are underway, with $20 million in annual savings already realized and an additional $10 million targeted, the company's financial health remains concerning given the rapid cash depletion and revenue decline.

Medical Device Industry Expert

Cutera's struggles reflect broader challenges in the aesthetics industry, particularly in North America. The 41% growth in AviClear sales internationally is a bright spot, suggesting potential in markets outside the U.S. The launch of Xeo+ also shows promise, indicating the company is still innovating despite financial pressures.

The promotion of Steve Kreider to SVP of North America could bring fresh perspective to the struggling region, given his extensive experience in dermatology and aesthetics. However, the company's ability to navigate the challenging market environment will depend on successfully executing its strategies around AviClear expansion, including training, marketing and clinical indication expansion.

The 7% growth in service revenue is a positive sign, indicating improved customer support. This could be important for maintaining customer loyalty during this difficult period. However, the overall financial picture suggests Cutera may face significant hurdles in regaining its market position without a substantial turnaround in North American sales.

BRISBANE, Calif.--(BUSINESS WIRE)-- CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024.

• Consolidated revenue for the second quarter of 2024 of $34.4 million
• Cash, cash equivalents, and restricted cash of $84.3 million
• AviClear growth of 41% vs prior year period driven by international capital system sales
• Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support
• Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization alignment

“The second quarter was challenging for Cutera and for the aesthetics industry in general. While AviClear experienced continued momentum internationally, and our launch of Xeo+ is off to a promising start, our overall performance did not meet expectations, particularly in North America,” commented Taylor Harris, Chief Executive Officer of Cutera, Inc. “We are responding to the challenging market environment with new commercial leadership in North America, additional cost reductions, and continued focus on building the AviClear franchise through training and education, cooperative marketing, launches in new international markets, and clinical indication expansion.”

Steve Kreider Promoted to Senior Vice President, North America

In July 2024, Steve Kreider was promoted to Senior Vice President (SVP), North America, with leadership responsibility for the combined North American commercial organization, including sales, marketing and customer excellence. Mr. Kreider joined Cutera in 2022 as SVP, Global Marketing, and brings close to 20 years of experience in dermatology and aesthetics, having served in prior commercial and business development leadership roles at Ortho Dermatologics, Merz Aesthetics, and Medicis.

Taylor Harris commented: “I am thrilled to appoint Steve to this role, and I’m confident that he is the right leader to unify our commercial efforts to best serve our customers. Steve brings tremendous passion for building great teams and culture, as well as deep experience in our space, all of which will serve Cutera well.”

Second Quarter 2024 Financial Highlights

Consolidated revenue for the second quarter of 2024 was $34.4 million, a decrease of 44% compared to the second quarter 2023. Revenue in the second quarter of 2023 included skincare revenue of $9.4 million and as the skincare distribution agreement was terminated in February 2024, the second quarter of 2024 did not have skincare revenue. Revenue related to capital systems sales declined 39%, while recurring sources of revenue, excluding skincare, declined 20%.

Gross profit was $7.6 million, or 22.2% of revenue for the second quarter of 2024, compared to a gross profit of $26.1 million, or 42.2% of revenue, for the second quarter of 2023. On a non-GAAP basis, gross profit was $9.6 million, or 28.0% of revenue, for the second quarter of 2024, compared to $28.8 million, or 46.6%, for the second quarter of 2023. Gross profit in the second quarter, on a GAAP and a non-GAAP basis, was negatively affected by approximately $2.4 million, or 6.9% of revenue, of expense related to excess and obsolete inventory.

Operating expenses were $29.4 million for the second quarter of 2024, compared to $57.2 million in the prior year period. On a non-GAAP basis, operating expenses were $30.9 million for the second quarter of 2024, compared to $42.1 million for the prior year period.

GAAP operating loss was $21.8 million and $31.2 million for the second quarters of 2024 and 2023, respectively. Non-GAAP operating loss was $21.3 million for the second quarter of 2024, compared to a loss of $13.2 million for the second quarter of 2024.

Cash, cash equivalents, and restricted cash, were $84.3 million as of June 30, 2024, compared to $105.4 million as of March 31, 2024.

Cost Restructuring

During the second quarter, the company completed the global restructuring program that was initiated in the fourth quarter of 2023, which resulted in expense savings of approximately $20 million on an annualized basis. In addition to that program, the company has identified an additional $10 million cost reduction opportunity, which should be fully realized in 2025.

2024 Outlook

Management is revising full year revenue guidance to $140 million to $145 million, compared to previous revenue guidance of $160 million to $170 million. Cash, cash equivalents, and restricted cash guidance is updated to approximately $40 million at December 31, 2024, from the Company’s previous guidance of a range from $55 million to $60 million.

Conference Call

The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Shelby Eckerman, Vice President, Finance.

Participants can register for the conference call by following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open until the end of the live conference call.

If participants prefer to dial in and speak with an operator, dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. It is recommended that you call in 10 minutes prior to the scheduled start time if you are using one of these operator-assisted phone numbers.

The call will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and income or loss from operations. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning (“ERP”) implementation costs, certain legal and litigation costs, certain executive and non-recurring severance costs, retention plan costs, gain on termination of a distribution agreement, and certain other adjustments. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

The Company defines non-GAAP financial measure, also commonly known as adjusted EBITDA, as operating income before depreciation and amortization, stock-based compensation, ERP implementation costs, certain legal and litigation costs, severance, retention plan costs, gain on early termination of distribution agreement, and other adjustments.

Company management uses non-GAAP measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency, making it difficult to contribute to a meaningful evaluation of the Company’s operating performance;

Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics as well as the settlement of $5.8 million, which is not part of the Company’s ordinary course of business. The Company’s complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. The Company excludes these costs as well as the settlement because this litigation is a result of a discrete event that was not part of the Company’s business strategy, but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of the Company’s core operations;

Severance. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company’s strategy, but its costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company’s business strategy but could have a significant impact on the results of operation;

Retention plan costs. The Company has excluded the expense related to a retention plan implemented in April 2023. Approximately $11 million was made available to sales personnel and key employees. The Company expects the final aggregate payments under the retention plan will be approximately $7 million with the final installment occurring in October 2024. The Company has excluded expense related to this retention plan as such costs are not considered part of ongoing operations; and

Gain on early termination of distribution agreement. The Company has excluded a gain recorded in connection with the early termination of a distribution agreement with ZO USA in calculating its non-GAAP operating expenses and non-GAAP operating income. The Company recorded the net gain of $9.7 million in the Company's condensed consolidated statement of operations for the three months ended March 31, 2024. The Company has excluded this gain as it is not indicative of the ongoing financial performance of the business, and not part of the Company’s business strategy.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to, Cutera’s plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All statements made in this release are made only as of the date set forth at the beginning of this release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the second quarter ended June 30, 2024, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
	June 30,				December 31,
	2024				2023
Assets
Current assets:
Cash and cash equivalents	$	83,115			$	143,612
Accounts receivable, net		34,554				43,121
Inventories		80,353				62,600
Other current assets and prepaid expenses		12,961				19,852
Total current assets		210,983				269,185
Long-term inventories		13,825				16,283
Property and equipment, net		28,140				37,275
Deferred tax asset		508				579
Restricted cash		1,196				-
Goodwill		1,339				1,339
Operating lease right-of-use assets		11,388				10,055
Other long-term assets		8,916				11,575
Total assets	$	276,295			$	346,291
Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable	$	17,617			$	19,829
Accrued liabilities		30,356				55,055
Operating leases liabilities		3,382				2,441
Deferred revenue		8,798				10,422
Total current liabilities		60,153				87,747
Deferred revenue, net of current portion		1,507				1,494
Operating lease liabilities, net of current portion		9,223				8,887
Convertible notes, net of unamortized debt issuance costs		419,841				418,695
Other long-term liabilities		1,242				1,298
Total liabilities		491,966				518,121
Stockholders’ deficit:
Common stock		20				20
Additional paid-in capital		135,114				131,496
Accumulated deficit		(350,805	)			(303,346	)
Total stockholders' deficit		(215,671	)			(171,830	)
Total liabilities and stockholders' deficit	$	276,295			$	346,291

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
	Three Months Ended								Six Months Ended
	June 30,				June 30,				June 30,				June 30,
	2024				2023				2024				2023
Products	$	28,357			$	56,175			$	61,472			$	105,296
Service		6,020				5,650				11,698				11,055
Total net revenue		34,377				61,825				73,170				116,351
Products		23,765				32,051				47,054				62,110
Service		2,968				3,691				6,053				6,526
Total cost of revenue		26,733				35,742				53,107				68,636
Gross profit		7,644				26,083				20,063				47,715
Gross margin %		22.2	%			42.2	%			27.4	%			41.0	%
Operating expenses:
Sales and marketing		20,664				33,271				44,341				62,783
Research and development		4,463				5,784				9,464				12,252
General and administrative		4,321				18,191				17,202				30,444
Gain on early termination of distribution agreement		-				-				(9,708	)			-
Total operating expenses		29,448				57,246				61,299				105,479
Loss from operations		(21,804	)			(31,163	)			(41,236	)			(57,764	)
Amortization of debt issuance costs		(575	)			(557	)			(1,146	)			(1,109	)
Interest on convertible notes		(2,959	)			(2,958	)			(5,898	)			(5,897	)
Interest income		1,025				2,179				2,480				4,658
Other expense, net		(387	)			(453	)			(1,703	)			(616	)
Loss before income taxes		(24,700	)			(32,952	)			(47,503	)			(60,728	)
Income tax expense (benefit)		(19	)			326				(44	)			598
Net loss	$	(24,681	)		$	(33,278	)		$	(47,459	)		$	(61,326	)
Net loss per share:
Basic	$	(1.23	)		$	(1.68	)		$	(2.37	)		$	(3.09	)
Diluted	$	(1.23	)		$	(1.68	)		$	(2.37	)		$	(3.09	)
Weighted-average number of shares used in per share calculations:
Basic		20,091				19,858				20,041				19,819
Diluted		20,091				19,858				20,041				19,819

CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)
		Three Months Ended								% Change		Six Months Ended								% Change
		June 30,				June 30,				2024 Vs		June 30,				June 30,				2024 Vs
		2024				2023				2023		2024				2023				2023
Revenue By Geography:
North America		$	15,980			$	32,437			-50.7%		$	34,371			$	59,639			-42.4%
Japan			3,829				12,810			-70.1%			11,427				25,718			-55.6%
Rest of World			14,568				16,578			-12.1%			27,372				30,994			-11.7%
Total Net Revenue		$	34,377			$	61,825			-44.4%		$	73,170			$	116,351			-37.1%
International as a percentage of total revenue			53.5	%			47.5	%					53.0	%			48.7%
Revenue By Product Category:
Systems
- North America		$	9,814			$	23,598			-58.4%		$	21,673			$	42,768			-49.3%
- Rest of World (including Japan)			14,086				15,664			-10.1%			26,487				31,036			-14.7%
Total Systems			23,900				39,262			-39.1%			48,160				73,804			-34.7%
Consumables			4,457				7,491			-40.5%			9,112				13,938			-34.6%
Skincare			-				9,422			-100.0%			4,200				17,554			-76.1%
Total Products			28,357				56,175			-49.5%			61,472				105,296			-41.6%
Service			6,020				5,650			+6.5%			11,698				11,055			+5.8%
Total Net Revenue		$	34,377			$	61,825			-44.4%		$	73,170			$	116,351			-37.1%
		Three Months Ended										Six Months Ended
		June 30,				June 30,						June 30,				June 30,
		2024				2023						2024				2023
Pre-tax Stock-Based Compensation Expense:
Cost of revenue		$	144			$	361					$	293			$	725
Sales and marketing			404				1,283						970				2,431
Research and development			264				415						569				1,108
General and administrative			781				(509	)					1,870				672
		$	1,593			$	1,550					$	3,702			$	4,936

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
	Three Months Ended								Six Months Ended
	June 30,				June 30,				June 30,				June 30,
	2024				2023				2024				2023
Cash flows from operating activities:
Net loss	$	(24,681	)		$	(33,278	)		$	(47,459	)		$	(61,326	)
Adjustments to reconcile net loss to net cash provided used in operating activities:
Stock-based compensation		1,593				1,550				3,702				4,936
Depreciation and amortization		1,804				1,829				3,795				3,238
Amortization of contract acquisition costs		1,378				1,891				2,769				4,069
Amortization of debt issuance costs		575				557				1,146				1,109
Deferred tax assets		26				30				71				43
Provision for credit losses		2,627				1,689				4,808				1,914
Unrealized gain on foreign exchange forward		-				623				-				-
Accretion of discount on investment securities and investment income, net		-				180				-				146
Changes in assets and liabilities:
Accounts receivable		(287	)			(3,621	)			3,634				(10,031	)
Inventories		2,879				5,627				(8,582	)			(536	)
Other current assets and prepaid expenses		6,332				1,277				6,892				(776	)
Other long-term assets		(90	)			(2,771	)			(330	)			(4,782	)
Accounts payable		4,301				(336	)			(2,212	)			(1,666	)
Accrued liabilities		(16,525	)			(5,512	)			(24,441	)			(3,806	)
Operating leases, net		(26	)			(14	)			(56	)			(30	)
Deferred revenue		(150	)			308				(1,611	)			509
Net cash used in operating activities		(20,244	)			(29,971	)			(57,874	)			(66,989	)
Cash flows from investing activities:
Acquisition of property and equipment		(882	)			(14,755	)			(1,217	)			(25,108	)
Proceeds from maturities of marketable investments		6				58,705				63				152,859
Purchases of marketable investments		-				-				-				(23,467	)
Net provided by (used in) cash used in investing activities		(876	)			43,950				(1,154	)			104,284
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan		-				749				-				858
Taxes paid related to net share settlement of equity awards		(20	)			(789	)			(84	)			(3,186	)
Payments on finance lease obligation		7				(113	)			(189	)			(237	)
Net cash provided by (used in) financing activities		(13	)			(153	)			(273	)			(2,565	)
Net increase (decrease) in cash, cash equivalents and restricted cash		(21,133	)			13,826				(59,301	)			34,730
Cash, cash equivalents, and restricted cash at beginning of period		105,444				167,528				143,612				146,624
Cash, cash equivalents, and restricted cash at end of period	$	84,311			$	181,354			$	84,311			$	181,354

CUTERA, INC. Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (in thousands)
Three Months Ended June 30, 2024		Gross Profit				Gross Margin		Operating Expenses				Operating Income
Reported		$	7,644			22.2%			29,448			$	(21,804	)
Adjustments:
Depreciation and amortization including contract acquisition costs			1,826			5.3%			1,357				3,183
Stock-based compensation			144			0.4%			1,449				1,593
Legal - Lutronic settlement						0.0%			(5,750	)			(5,750	)
Severance			4			0.0%			676				680
Retention plan costs			7			0.0%			821				828
Gain on early termination of distribution agreement			-			0.0%			-				-
Other adjustments			-			0.0%			-				-
Total adjustments			1,981			5.8%			(1,447	)			534
Non-GAAP		$	9,625			28.0%		$	30,895			$	(21,270	)
Three Months Ended June 30, 2023		Gross Profit				Gross Margin		Operating Expenses				Operating Income
Reported		$	26,083			42.2%			57,246			$	(31,163	)
Adjustments:
Depreciation and amortization including contract acquisition costs			1,998			3.2%			1,993				3,991
Stock-based compensation			361			0.6%			1,189				1,550
ERP implementation cost			-			0.0%			770				770
Legal - Lutronic expense			-			0.0%			394				394
Severance			-			0.0%			234				234
Retention plan costs			65			0.1%			2,907				2,972
Board of Directors legal and advisory fees			-			0.0%			7,709				7,709
Other adjustments			307			0.5%			-				307
Total adjustments			2,731			4.4%			15,196				17,927
Non-GAAP		$	28,814			46.6%		$	42,050			$	(13,236	)

Six Months Ended June 30, 2024		Gross Profit				Gross Margin		Operating Expenses				Operating Income
Reported		$	20,063			27.4%			61,299			$	(41,236	)
Adjustments:
Depreciation and amortization including contract acquisition costs			3,921			5.4%			2,644				6,565
Stock-based compensation			293			0.4%			3,409				3,702
Legal - Lutronic settlement			-			0.0%			(5,750	)			(5,750	)
Severance			96			0.1%			803				899
Retention plan costs			55			0.1%			3,572				3,627
Gain on early termination of distribution agreement			-			0.0%			(9,708	)			(9,708	)
Other adjustments			-			0.0%			263				263
Total adjustments			4,365			6.0%			(4,767	)			(402	)
Non-GAAP		$	24,428			33.4%		$	66,066			$	(41,638	)
Six Months Ended June 30, 2023		Gross Profit				Gross Margin		Operating Expenses				Operating Income
Reported		$	47,715			41.0%			105,479			$	(57,764	)
Adjustments:
Depreciation and amortization including contract acquisition costs			3,597			3.1%			3,981				7,578
Stock-based compensation			725			0.6%			4,211				4,936
ERP implementation cost			-			0.0%			1,288				1,288
Legal - Lutronic expense			-			0.0%			1,046				1,046
Severance			119			0.1%			430				549
Retention plan costs			65			0.1%			2,907				2,972
			-			0.0%			7,709				7,709
Other adjustments			307			0.3%			585				892
Total adjustments			4,813			4.1%			22,157				26,970
Non-GAAP		$	52,528			45.1%			83,322			$	(30,794	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808553412/en/

Cutera Investor Relations Contact:

Shelby Eckerman, VP, Finance

IR@Cutera.com

Source: Cutera, Inc.

FAQ

What was Cutera's revenue for Q2 2024?

Cutera (CUTR) reported consolidated revenue of $34.4 million for the second quarter of 2024.

How did AviClear perform in Q2 2024 for Cutera?

AviClear experienced growth of 41% compared to the prior year period, driven by international capital system sales.

What is Cutera's revised revenue guidance for 2024?

Cutera (CUTR) revised its full-year 2024 revenue guidance to $140 million to $145 million, down from the previous guidance of $160 million to $170 million.

Who was appointed as the new Senior Vice President for North America at Cutera?

Steve Kreider was promoted to Senior Vice President, North America, with leadership responsibility for the combined North American commercial organization at Cutera (CUTR).

What cost reduction initiatives did Cutera announce in Q2 2024?

Cutera (CUTR) completed a global restructuring program initiated in Q4 2023, saving approximately $20 million annually, and identified an additional $10 million cost reduction opportunity to be realized in 2025.